Peptic Ulcers - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Peptic Ulcers - Pipeline Review, H1 2016

Peptic Ulcers - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Peptic Ulcers - Pipeline Review, H1 2016
Published Jun 15, 2016
57 pages — Published Jun 15, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Peptic Ulcers - Pipeline Review, H1 2016, provides an overview of the Peptic Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peptic Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers
- The report reviews pipeline therapeutics for Peptic Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peptic Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Peptic Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peptic Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in

  
Source:
Document ID
GMDHC8193IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Peptic Ulcers Overview71
Therapeutics Development81
  Pipeline Products for Peptic Ulcers Overview81
Peptic Ulcers Therapeutics under Development by Companies91
Peptic Ulcers Pipeline Products Glance102
  Clinical Stage Products101
  Early Stage Products111
Peptic Ulcers Products under Development by Companies121
Peptic Ulcers Companies Involved in Therapeutics Development1310
  Ache Laboratorios Farmaceuticos S/A131
  Astellas Pharma Inc.141
  ChoDang Pharm Co., Ltd.151
  Daewoong Pharmaceutical Co., Ltd.161
  Kukje Pharmaceutical Industry Co., Ltd.171
  RaQualia Pharma Inc.181
  Sequella, Inc.191
  Sihuan Pharmaceutical Holdings Group Ltd.201
  Sinil Pharmaceutical Co., Ltd211
  Yooyoung Pharmaceutical Co., Ltd.221
Peptic Ulcers Therapeutics Assessment238
  Assessment by Monotherapy Products231
  Assessment by Combination Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration291
  Assessment by Molecule Type301
Drug Profiles3117
  (ecabet + ranitidine) Drug Profile311
  (lansoprazole + omeprazole) Drug Profile321
  anaprazole sodium Drug Profile331
  ASP-6537 Drug Profile341
  DWJ-206 Drug Profile351
  KJ-14001 Drug Profile361
  PDI-39 Drug Profile371
  PMKS-005 Drug Profile381
  RQ-00000774 Drug Profile391
  SI-001002 SR Drug Profile401
  Small Molecule to Inhibit Proton Pump for Peptic Ulcers Drug Profile411
  Small Molecules for Gastric Ulcers Drug Profile421
  SQ-109 Drug Profile434
  YYD-601 Drug Profile471
Peptic Ulcers Dormant Projects482
Peptic Ulcers Discontinued Products501
Peptic Ulcers Product Development Milestones515
  Featured News &Press Releases511
    Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies511
    Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers521
    Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck521
    Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations531
    Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy531
    Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)541
    Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)541
    Jun 01, 2007: AstraZeneca s Prilosec Patents Upheld By Court551
    Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court551
Appendix562
  Methodology561
  Coverage561
  Secondary Research561
  Primary Research561
  Expert Panel Validation561
  Contact Us561
  Disclaimer571

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Peptic Ulcers - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Peptic-Ulcers-Pipeline-Review-H1-2016-2088-15949>
  
APA:
Global Markets Direct - Market Research. (2016). Peptic Ulcers - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Peptic-Ulcers-Pipeline-Review-H1-2016-2088-15949>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.